Nulisa (a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing) testing services to identify biomarkers that provide information about the underlying molecular…
Active Purchase Order Awarded Last action
- Contract number
- 75N98026P00871
- Awardee
-
Banner Health UEI SB35ENJFKK14
- Awarding agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,332,200
Award facts
- Opportunity
-
- Neurodegenerative Disease Research - Proteomic Analysis Services Pre-Solicitation · NIHNOI26PCANIA01589 · Posted May 13, 2026
- Contract value 33% obligated
-
- $2,332,200.00 Current, with exercised options
- $6,996,600.00 Potential, with all options
- Completion date 8% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute on Aging National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- North Bethesda, MD 20852, USA
Award details come from SAM.gov/FPDS.
About this award
The National Institute on Aging awarded a purchase order to Banner Health (operating as Banner Research Institute) for $6,996,600 on August 1, 2026, for NULISA proteomic liquid biopsy testing services to identify biomarkers associated with Alzheimer's disease and related dementias. Work is performed in North Bethesda, Maryland. The order carries a firm fixed price and runs through July 31, 2029, comprising a 12-month base period beginning August 1, 2026, and two optional 12-month renewal periods. The procurement was conducted as a sole-source acquisition under 41 U.S.C. 3304(a)(1); Banner Health maintains a validated, biobanked NULISA quality control cohort specifically designed to ensure longitudinal analytical consistency and dataset harmonization that no alternate vendor could replicate without unacceptable delay or scientific risk. The requirement is classified under NAICS 541380 (Testing Laboratories and Services) and PSC Q301 (Reference Laboratory Testing).
Description
Nulisa (a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing) testing services to identify biomarkers that provide information about the underlying molecular changes associated with ad/adrd.
Quick answers
Who was awarded contract 75N98026P00871?
75N98026P00871 was awarded to Banner Health by Office of Logisitics and Acquisition Operations (National Institutes of Health) on August 1, 2026.
How much is contract 75N98026P00871 worth?
The government has obligated $2,332,200 on 75N98026P00871. Its potential value, with all options, is $6,996,600.
Which agency awarded contract 75N98026P00871?
Office of Logisitics and Acquisition Operations (National Institutes of Health) awarded 75N98026P00871, with funding from National Institute on Aging (National Institutes of Health).
Was contract 75N98026P00871 competed?
The extent of competition for 75N98026P00871 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award